111In-octreotide is superior to 123I- metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas

Journal of Nuclear Medicine

Volumn 49, Issue 8, 2008, Pages 1232-1237

  Koopmans, Klaas Pieter ^a   Jager, Pieter L ^a   Kema, Ido P ^a   Kerstens, Michiel N ^a   Albersy, Frans ^a   Dullaart, Robin P F ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Accuracy; Endocrinology; MIBG scintigraphy; Neuroendocrine; Octreotide scintigraphy; Oncology; Paraganglioma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; METADRENALIN; NORMETADRENALIN; PENTETREOTIDE IN 111; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; INDIUM; INDIUM 111 OCTREOTIDE; INDIUM-111-OCTREOTIDE; OCTREOTIDE; RADIOACTIVE IODINE; SOMATOSTATIN RECEPTOR;

ADULT; AGED; ARTICLE; CARCINOID; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; FEMALE; HOSPITAL DEPARTMENT; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT CARE; PARAGANGLIOMA; PATIENT REFERRAL; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIVERSITY HOSPITAL; COMPARATIVE STUDY; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; RADIOGRAPHY; SCINTISCANNING;

3-IODOBENZYLGUANIDINE; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OCTREOTIDE; PARAGANGLIOMA; RECEPTORS, SOMATOSTATIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 48749127110     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.107.047738     Document Type: Article

References (24)

1. Lee JH, Barich F, Karnell LH, et al. National Cancer Data Base report on malignant paragangliomas of the head and neck. Cancer. 2002;94:730-737.
2. Baysal BE, Willett-Brozick JE, Lawrence EC, et al. Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet. 2002;39:178-183.
3. Timmers HJ, Kozupa A, Chen CC, et al. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma. J Clin Oncol. 2007;25:2262-2269.
4. McCaffrey TV, Myssiorek D, Marrinan M. Head and neck paragangliomas: physiology and biochemistry. Otolaryngol Clin North Am. 2001;34:837-844.
5. Duet M, Sauvaget E, Petelle B, et al. Clinical impact of somatostatin receptor scintigraphy in the management of paragangliomas of the head and neck. J Nucl Med. 2003;44:1767-1774.
6. 123I-MIBG scintigraphy in the diagnosis and location of chemodectoma. Nucl Med Commun. 1998;19:735-742.
7. Pearse AG. The APUD cell concept and its implications in pathology. Pathol Annu. 1974;9:27-41.
8. Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86:5210-5216.
9. Maurea S, Cuocolo A, Reynolds JC, et al. Iodine-131- metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med. 1993;34:173-179.
10. Kwekkeboom DJ, van Urk H, Pauw BK, et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med. 1993;34:873-878.
11. Somatostatine-receptor-scintigrafie. In: Urk P, Barneveld PC, eds. Aanbevelingen Nucleaire Geneeskunde. Neer, The Netherlands: Kloosterhof Acquisitie Services-Uitgeverij; 2007:64-67.
12. MIBG-scintigrafie. In: Urk P, Barneveld PC, eds. Aanbevelingen Nucleaire Geneeskunde. Neer, The Netherlands: Kloosterhof Acquisitie Services-Uitgeverij; 2007:60-63.
13. Strobel K, Skalsky J, Kalff V, et al. Tumour assessment in advanced melanoma: value of FDG-PET/CT in patients with elevated serum S-100B. Eur J Nucl Med Mol Imaging. 2007;34:1366-1375.
14. 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008 20;26:1489-1495.
15. 18F- dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation. J Nucl Med. 2008;49:524-531.
16. 18F-DOPA PET: a prospective, diagnostic accuracy study. Lancet Oncol. 2006;7:728-734.
17. Kema IP, Meiborg G, Nagel GT, Stob GJ, Muskiet FA. Isotope dilution ammonia chemical ionization mass fragmentographic analysis of urinary 3O-methylated catecholamine metabolites: rapid sample clean-up by derivatization and extraction of lyophilic samples. J Chromatogr Biomed Appl. 1993;671:181-189.
18. Kema IP, de Vries EG, Slooff MJ, Biesma B, Muskiet FA. Serotonin, catecholamines, histamine, and their metabolites in urine, platelets, and tumor tissue of patients with carcinoid tumors. Clin Chem. 1994;40:86-95.
19. 111In-DTPA-D-Phe1]-octreotide imaging. J Nucl Med. 2000;41:1793-1800.
20. van Houtum WH, Corssmit EP, Douwes Dekker PB, et al. Increased prevalence of catecholamine excess and phaeochromocytomas in a well-defined Dutch population with SDHD-linked head and neck paragangliomas. Eur J Endocrinol. 2005;152:87-94.
21. Brink I, Schaefer O, Walz M, Neumann HP. Fluorine-18 DOPA PET imaging of paraganglioma syndrome. Clin Nucl Med. 2006;31:39-41.
22. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging. 2003;30:689-694.
23. 18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab. 2003;88:4083-4087.
24. 177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med. 2006;47:1599-1606.